Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Medivir AB announces that data from the company’s leading program fostroxacitabine bralpamide and its potential effect on hepatocellular carcinoma, will be presented at the American Association for Cancer Research Annual Meeting, on April 14-19, in Orlando, USA.